Attuale ruolo: Professore Associato
SSD: MED/07
Edificio: F – Nord
Piano: II
Studio: 253
Telefono: 0672596553
Mail: ceccherini@med.uniroma2.it
Education
1994: Degree with honours (110/110 cum laude) in Pharmaceutical Chemistry and Technology at the University of Rome La Sapienza, Italy
2001: PhD in Biology (magna cum laude) at the University of Munich Ludwig-Maximilians, Germany
Academic and Research Activity
2008-2014: Assistant Professor at the Chair of Virology, Department of Experimental Medicine and Surgery, University of Rome Tor Vergata
2005-2011: Professor of Virology at the Science Faculty, University of L’Aquila
2014-today: Associate Professor at the Chair of Virology, Department of Experimental Medicine and Surgery, University of Rome Tor Vergata
She has been involved in research activity on viruses since 1996. Her research interests and expertise are on HIV infection, antiviral drugs, HIV-HBV-HCV drug-resistance, viral pathogenesis, viral tropism, viral evolution and dynamics, genotypic (by Sanger and NGS sequencing), structural and functional analysis of viral proteins.
She cooperates with many nationally and internationally recognized scientific researchers through several grants from the Italian National Institute of Health, the Ministry of University and Scientific Research, and the European Community.
She published 143 full papers in prestigious journals, with a median impact factor of 4.8; H index of 27, total N° of citations: 2311.
She attended at numerous national and international scientific meetings presenting her work, by more than 200 oral presentations, 100 posters, and 55 invited lectures.
She is a member of the scientific committee of the Italian Cohort of Antiretroviral-Naïve Patients (ICONA) Foundation, and from 2014 also a member of the Coordinator and Scientific Comity of the Italian Association of Liver Study (AISF). She is a member of the editorial board in PLoS ONE and AIDS Reviews, and acts as a reviewer for many journals peer reviewed (as J Clin Microbiol, Clin Microbiol Infect, J Ant Chem, Antiv Therapy, J Infect Dis, AIDS Rev, Retrovirol, Eur J Clin Micr & Infect Dis., PLoS Pathogens, HIV Medicine, PLOS ONE, J of Virol) Median of revised articles/year: 20.
Awards
G. B. Rossi 2008 prize, as the best researcher in the HIV-field for the best publication (F. Ceccherini Silberstein et al., J Virol 2007, 81), and 10 awards as a best oral or poster at National and International Conferences.
Titoli accademici e di studio
1994: Laurea con Lode in Chimica e Tecnologie Farmaceutiche presso l’Università di Roma La Sapienza
1997-1998: Borsa annuale Fondazione Cenci Bolognetti per l’estero dell’Università di Roma La Sapienza
2001: PhD in Biologia con votazione Magna cum Laude presso l’Università Ludwig Maximilian di Monaco di Baviera, Germania
2000-2002: Borsa annuale AIDS (e rinnovo) dell’Istituto Superiore di Sanità
2002-2007: Assegnista di Ricerca presso il Laboratorio di Virologia, Facoltà di Medicina e Chirurgia dell’Università di Roma Tor Vergata
2008-2014: Ricercatore, presso la Facoltà di Medicina e Chirurgia dell’Università di Roma Tor Vergata per il settore scientifico disciplinare MED/07, confermato in data 1/10/2011
2005-2011: Professore a contratto di Virologia (4 CFU) presso la Facoltà di Scienze MM.FF.NN dell’Università di L’Aquila
Attività didattica:
Titolare dei seguenti insegnamenti dell’Università degli Studi di Roma Tor Vergata:
Microbiology and Immunology (6 CFU) per la Laurea Magistrale in Farmacia in lingua inglese
Virologia Speciale (1 CFU), per il C.I. di Microbiologia e Microbiologia Clinica per la Laurea Triennale in Tecniche Diagnostiche di Laboratorio Biomedico
Inoltre, svolge lezioni integrative a Tor Vergata per: il Corso Integrato di Microbiologia e Virologia (3 CFU), per la Laurea specialistica in Medicina e Chirurgia; il Corso Integrato di Microbiology and Virology (4 CFU), per la Laurea specialistica in Medicina e Chirurgia in lingua inglese; Summer School for International Health (5 CFU), Facoltà di Medicina e Chirurgia
Docente al Corso The advanced training in the clinical interpretation of drug resistance testing results, dell’Università Cattolica di Lovanio, Belgio
Docente al Residential Course on Clinical Pharmacology of Antiretrovirals dell’Università di Torino.
Membro del collegio dei docenti del Corso di Dottorato di Microbiologia Medica e Immunologia, Facoltà di Medicina e Chirurgia
Attività scientifica
E’ Autrice di 147 lavori scientifici (oltre a più di 350 presentazioni a congressi), di cui 143 articoli pubblicati su riviste internazionali indicizzate (34 come membro di Collaborative Groups). Ha un Impact Factor medio: 4.8; Indice H: 27; N. totale di citazioni:2311; 55 Letture a invito a Congressi Nazionali e/o Internazionali
Le pubblicazioni riguardano i seguenti argomenti: infezione di HIV-1 in cellule del sistema nervoso centrale; meccanismi di resistenza ai farmaci antivirali (anti-HIV, HBV, HCV); meccanismi virologici che predicono o condizionano la risposta alla terapia antivirale nelle malattie croniche da HIV, HBV e HCV; meccanismi virologici che correlano con la replicazione ed espressione dell’infezione virale e progressione di malattia associata; analisi genotipica, strutturale e funzionale di proteine virali; analisi di quasispecie minoritarie di resistenza mediante sequenziamento massivo (UDPS).Ha ricevuto 11 premi personali a riconoscimento della propria attività scientifica
Incarichi speciali
2014-2016: Membro del Comitato Coordinatore e Scientifico dell’Associazione Italiana per lo Studio del Fegato (AISF).
2013-oggi: Membro dell’World Health Organization Surveillance HIV Drug Resistance Mutations Working Group.
2013-oggi: Membro della commissione didattica del Corso di Laurea Magistrale in Farmacia.
2012-oggi: Membro del Comitato di Segreteria della Fondazione ICONA (Italian Cohort of Anitretroviral-Naive Patients) e dal 2006 Membro del Comitato Scientifico Operativo
2010-oggi: Membro dell’”European HIV Drug Resistance Guidelines Panel” per la stesura delle Raccomandazioni Europee sull’uso clinico del test di resistenza HIV
Attività editoriale
2013-oggi: Membro dell’editorial board di PLoS ONE e AIDS Reviews.
2007-oggi: Revisore stabile od occasionale di articoli scientifici inviati a riviste “peer reviewed” (tra cui J. Clin. Microbiol., Clin. Microbiol. Infect., J. Antimicrob. Chemother., Antiviral Therapy, J. Infect. Dis., AIDS Reviews, Retrovirology, Eur. J. Clin. Micr & Infect. Dis., PLoS Pathogens, HIV Medicine, PLoS ONE, AIDS, Digestive and Liver Disease, J of Virology, J of Hepatology). Media di articoli scientifici revisionati/anno: 20
Pubblicazioni ultimi 5 anni/oppure quelle più rilevanti
Ceccherini Silberstein F, Di Maio VC, Aragri M, Ciotti M, Cento V, Perno CF. Hepatitis C Virus Gene Sequencing as a Tool for Precise Genotyping in the Era of New Direct Antiviral Agents. Hepatology. 2015 May 14. IF 11.190.
Alteri C, Surdo M, Bellocchi MC, Saccomandi P, Continenza F, Armenia D, Parrotta L, Carioti L, Costa G, Fourati S, Di Santo F, Scutari R, Barbaliscia S, Fedele V, Carta S, Balestra E, Alcaro S, Marcelin AG, Calvez V, Ceccherini-Silberstein F, Artese A, Perno CF, Svicher V. Incomplete Apobec3G/F neutralization by HIV-1 Vif mutations facilitates the genetic evolution from CCR5 to CXCR4 usage. Antimicrob Agents Chemother. 2015 Jun 8. IF 4.451
Armenia D, Fabeni L, Alteri C, Di Pinto D, Di Carlo D, Bertoli A, Gori C, Carta S, Fedele V, Forbici F, D’Arrigo R, Svicher V, Berno G, Pizzi D, Nicastri E, Sarmati L, Pinnetti C, Ammassari A, D’Offizi G, Latini A, Andreoni M, Antinori A, Ceccherini-Silberstein F, Perno CF, Santoro MM. HIV-1 integrase genotyping is reliable and reproducible for routine clinical detection of integrase resistance mutations even in patients with low-level viraemia. J Antimicrob Chemother. 2015 Jun;70(6):1865-73. IF 5.439
Cento V, Tontodonati M, Di Maio VC, Bellocchi MC, Valenti F, Manunta A, Fortuna S, Armenia D, Carioti L, Antonucci FP, Bertoli A, Trave F, Cacciatore P, Angelico M, Navarra P, Neumann AU, Vecchiet J, Parruti G, Babudieri S, Perno CF, Ceccherini-Silberstein F. Kinetics of hepatitis C virus RNA decay, quasispecies evolution and risk of virological failure during telaprevir-based triple therapy in clinical practice. Dig Liver Dis. 2015 Mar;47(3):233-41. IF 2.889
Surdo M, Alteri C, Puertas MC, Saccomandi P, Parrotta L, Swenson L, Chapman D, Costa G, Artese A, Balestra E, Aquaro S, Alcaro S, Lewis M, Clotet B, Harrigan R, Valdez H, Svicher V, Perno CF, Martinez-Picado J, Ceccherini-Silberstein F. Effect of maraviroc on non-R5 tropic HIV-1: refined analysis of subjects from the phase IIb study A4001029. Clin Microbiol Infect. 2015 Jan;21(1):103.e1-6. IF 5.197
Vingerhoets J, Calvez V, Flandre P, Marcelin AG, Ceccherini-Silberstein F, Perno CF, Mercedes Santoro M, Bateson R, Nelson M, Cozzi-Lepri A, Grarup J, Lundgren J, Incardona F, Kaiser R, Sonnerborg A, Clotet B, Paredes R, Günthard HF, Ledergerber B, Hoogstoel A, Nijs S, Tambuyzer L, Lavreys L, Opsomer M; Etravirine Cohort Study Group. Efficacy of etravirine combined with darunavir or other ritonavir-boosted protease inhibitors in HIV-1-infected patients: an observational study using pooled European cohort data. HIV Med. 2015 May;16(5):297-306. IF 3.454
Cozzi-Lepri A, Noguera-Julian M, Di Giallonardo F, Schuurman R, Däumer M, Aitken S, Ceccherini-Silberstein F, D’Arminio Monforte A, Geretti AM, Booth CL, Kaiser R, Michalik C, Jansen K, Masquelier B, Bellecave P, Kouyos RD, Castro E, Furrer H, Schultze A, Günthard HF, Brun-Vezinet F, Paredes R, Metzner KJ; CHAIN Minority HIV-1 Variants Working Group. Low-frequency drug-resistant HIV-1 and risk of virological failure to first-line NNRTI-based ART: a multicohort European case-control study using centralized ultrasensitive 454 pyrosequencing. J Antimicrob Chemother. 2015 Mar;70(3):930-40. IF 5.338 citazioni 3
Cento V, Di Paolo D, Di Carlo D, Micheli V, Tontodonati M, De Leonardis F, Aragri M, Antonucci FP, Di Maio VC, Mancon A, Lenci I, Manunta A, Taliani G, Di Biagio A, Nicolini LA, Nosotti L, Sarrecchia C, Siciliano M, Landonio S, Pellicelli A, Gasbarrini A, Vecchiet J, Magni CF, Babudieri S, Mura MS, Andreoni M, Parruti G, Rizzardini G, Angelico M, Perno CF, Ceccherini-Silberstein F. Hepatitis C virus RNA levels at week-2 of telaprevir/boceprevir administration are predictive of virological outcome. Dig Liver Dis. 2015 Feb;47(2):157-63. IF 2.889
Gianotti N, Cozzi-Lepri A, Antinori A, Di Biagio A, Moioli MC, Nozza S, Cingolani A, De Luca A, Madeddu G, Bonora S, Ceccherini-Silberstein F, Monforte Ad; ICONA Foundation Study. Durability of lopinavir/ritonavir dual-therapies in individuals with viral load <50 copies/mL in the observational setting. J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19799. IF 4.207
Di Maio VC, Cento V, Mirabelli C, Artese A, Costa G, Alcaro S, Perno CF, Ceccherini-Silberstein F. Hepatitis C Virus Genetic Variability and the Presence of NS5B Resistance-Associated Mutations as Natural Polymorphisms in Selected Genotypes Could Affect the Response to NS5B Inhibitors. Antimicrob Agents Chemother. 2014 May;58(5):2781-97. IF 4.565.
Santoro MM, Fabeni L, Armenia D, Alteri C, Di Pinto D, Forbici F, Bertoli A, Di Carlo D, Gori C, Carta S, Fedele V, D’Arrigo R, Berno G, Ammassari A, Pinnetti C, Nicastri E, Latini A, Tommasi C, Boumis E, Petrosillo N, D’Offizi G, Andreoni M, Ceccherini-Silberstein F, Antinori A, Perno CF. Reliability and clinical relevance of the HIV-1 drug resistance test in patients with low viremia levels. Clin Infect Dis. 2014 Apr;58(8):1156-64. IF 9.374.
Surdo M, Balestra E, Saccomandi P, Di Santo F, Montano M, Di Carlo D, Sarmati L, Aquaro S, Andreoni M, Svicher V, Perno CF, Ceccherini-Silberstein F. Inhibition of dual/mixed tropic HIV-1 isolates by CCR5-inhibitors in primary lymphocytes and macrophages. PLoS One. 2013 Jul 9;8(7):e68076. IF 4.092, citazioni 4.
Cento V, Landonio S, De Luca F, Di Maio VC, Micheli V, Mirabelli C, Niero F, Magni C, Rizzardini G, Perno CF, Ceccherini-Silberstein F. A boceprevir failure in a patient infected with HCV-genotype 1g: importance and limitations of virus genotyping prior to HCV protease inhibitor-based therapy. Antivir Ther. 2013;18(4):645-8. IF 3.161, citazioni 5.
Geretti AM, Armenia D, Ceccherini-Silberstein F. Emerging patterns and implications of HIV-1 integrase inhibitor resistance, Current Opinion in Infectious Diseases, post author corrections, 2012 Dec;25(6):677-86. IF 4.93, citazioni 17.
Armenia D, Vandenbroucke I, Fabeni L, Van Marck H, Cento V, D’Arrigo R, Van Wesenbeeck L, Scopelliti F, Micheli V, Bruzzone B, Lo Caputo S, Aerssens J, Rizzardini G, Tozzi V, Narciso P, Antinori A, Stuyver L, Perno CF, Ceccherini-Silberstein F. Study of genotypic and phenotypic HIV-1 dynamics of integrase mutations during raltegravir treatment: a refined analysis by ultra-deep 454 pyrosequencing. J Infect Dis. 2012; 205(4):557-67. IF 5.865, citazioni 23.
Cento V, Mirabelli C, Salpini R, Dimonte S, Artese A, Costa G, Mercurio F, Svicher V, Parrotta L, Bertoli A, Ciotti M, Di Paolo D, Sarrecchia C, Andreoni M, Alcaro S, Angelico M, Perno CF, Ceccherini-Silberstein F. HCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitors. PLoS One 2012;7(7):e39652. IF 4.092, citazioni 18.
Dimonte S., Mercurio F, Svicher V, D’Arrigo R, Perno CF, Ceccherini-Silberstein F. Selected amino acid mutations in HIV-1 B subtype gp41 are Associated with Specific gp120V3 signatures in the regulation of Co-Receptor usage. Retrovirology 2011; 12;8:33. IF 5.24, Citazioni 15.
Vandamme AM, Camacho RJ, Cecchesrini-Silberstein F, de Luca A, Palmisano L, Paraskevis D, Paredes R, Poljak M, Schmit JC, Soriano V, Walter H, Sönnerborg A; European HIV Drug Resistance Guidelines Panel. European recommendations for the clinical use of HIV drug resistance testing: 2011 update. AIDS Rev. 2011; 13(2):77-108. IF 4.786, Citazioni 58.
Malet I, Wirden M, Fourati S, Armenia D, Masquelier B, Fabeni L, Sayon S, Katlama C, Perno CF, Calvez V, Marcelin AG, Ceccherini-Silberstein F. Prevalence of resistance mutations related to integrase inhibitor S/GSK1349572 in HIV-1 subtype B raltegravir-naive and -treated patients. J Antimicrob Chemother. 2011; 66(7):1481-3. IF 5.068, Citazioni 13.
Svicher V, Balestra E, Cento V, Sarmati L, Dori L, Vandenbroucke I, D’Arrigo R, Buonomini AR, Van Marck H, Surdo M, Saccomandi P, Mostmans W, Aerssens J, Aquaro S, Stuyver LJ, Andreoni M, Ceccherini-Silberstein F, Perno CF. HIV-1 dual/mixed tropic isolates show different genetic and phenotypic characteristics and response to maraviroc in vitro. Antiviral Res. 2011; 90(1):42-53. IF 4.301, Citazioni 16.
Ceccherini-Silberstein F., Van Baelen K., Armenia D., Trignetti M., Rondelez E., Fabeni L., Scopelliti F., Pollicita M., Van Wesenbeeck L., Van Eygen V., Dori L., Sarmati L., Aquaro S., Palamara G., Andreoni M., Stuyver L. J, Perno CF. Secondary HIV-1 integrase resistance mutations, found as minority quasispecies in integrase therapy naive patients, have little or no effect on susceptibility to integrase inhibitors, Antimicrob. Agents Chemother. 2010; 54(9):3938-48. IF 4.672, Citazioni 29.
Ceccherini-Silberstein F., Cento V., Calvez V., Perno CF. The use of HIV resistance tests in clinical practice, Clin Microbiol Infect. 2010; 16(10):1511-7s. IF 4.784, Citazioni 13.
Ceccherini-Silberstein F., Malet I., Fabeni L., Dimonte S, Svicher V., D’Arrigo R., Artese A., Costa G., Bono S., Alcaro S., d’Arminio Monforte A., Katlama C., Calvez V., Antinori A., Marcelin A.G., Perno CF. Specific HIV-1 integrase polymorphisms change their prevalence in untreated versus antiretroviral-treated HIV-1-infected patients, all naive to integrase inhibitors. J. Antimicrob. Chemother. 2010; 65(11):2305-18. IF 4.038, Citazioni 20.
Ceccherini-Silberstein F., Malet I., D’Arrigo R., Antinori A., Marcelin AG., Perno CF. Characterization andstructural analysis of HIV-1 integrase conservation. AIDS Rev. 11:17-29, 2009. IF 3.786, citazioni 102.
Ceccherini-Silberstein F, Svicher V, Sing T, Artese A, Santoro MM, Forbici F, Bertoli A, Alcaro S, Palamara G, d’Arminio Manforte A, Balzarini J, Antinori A, Lengauer T, Perno CF. Characterization and structural analysis of novel mutations in human immunodeficiency virus type 1 reverse tyranscriptase involved in the regulation of resistance to nonnucleoside inhibitors. J Virol 81:11507-519, 2007. Awarded the GB Rossi 2008 Prize, as the best publication in Italy in HIV field. IF 5.332, citazioni 54.